Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Carcinoma, Squamous Cell 1

Interventions

Specimen Handling 113Magnetic Resonance Spectroscopy 113Cyclophosphamide 106pembrolizumab 82Radiotherapy 79Nivolumab 68Cisplatin 67fludarabine 64Carboplatin 59Biopsy 54Standard of Care 46Radiosurgery 43Gemcitabine 43Paclitaxel 42Dexamethasone 41Rituximab 37Radiation 37Doxorubicin 37Blood Specimen Collection 37Cytarabine 36Bevacizumab 35venetoclax 34fludarabine phosphate 33Surveys and Questionnaires 32Temozolomide 31Radiotherapy, Intensity-Modulated 31Capecitabine 31Practice Guidelines as Topic 28Etoposide 28Oxaliplatin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Tiragolumab × 30 days × Clear all
NCT05681039 2026-06-02

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
29 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡